The human IgG anti-carbohydrate repertoire exhibits a universal architecture and contains specificity for microbial attachment sites

Science Translational Medicine

Volumn 7, Issue 269, 2015, Pages

  Schneider, Christoph ^a   Smith, David F ^b   Cummings, Richard D ^b   Boligan, Kayluz Frias ^a   Hamilton, Robert G ^c   Bochner, Bruce S ^c,e   Miescher, Sylvia ^b   Simon, Hans Uwe ^a   Pashov, Anastas ^d   Vassilev, Tchavdar ^d   Von Gunten, Stephan ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b Protein Carbohydrate Interaction Core H Consortium for Functional Glycomics Department of Biochemistry ^*  (Switzerland)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d INSTITUTE OF MICROBIOLOGY   (Bulgaria)

^e NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOHYDRATE ANTIGEN; CARBOHYDRATE SPECIFIC IMMUNOGLOBULIN G ANTIBODY; CYTOMEGALOVIRUS ANTIBODY; EXOTOXIN; GLYCAN; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G2; LIGAND; RHESUS D ANTIBODY; UNCLASSIFIED DRUG; BACTERIAL ANTIGEN; BACTERIOPHAGE RECEPTOR; CARBOHYDRATE; EPITOPE; IMMUNOGLOBULIN; VIRUS ANTIGEN;

AFFINITY CHROMATOGRAPHY; ARTICLE; CONTROLLED STUDY; DRUG SPECIFICITY; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOREACTIVITY; MICROARRAY ANALYSIS; ANTIBODY SPECIFICITY; CHEMISTRY; DONOR; GLYCOBIOLOGY; HUMAN; IMMUNOLOGY;

ANTIBODY SPECIFICITY; ANTIGENS, BACTERIAL; ANTIGENS, VIRAL; ATTACHMENT SITES, MICROBIOLOGICAL; CARBOHYDRATES; EPITOPES; GLYCOMICS; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; LIGANDS; TISSUE DONORS;

EID: 84920719200     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3010524     Document Type: Article

References (64)

1. V. Brusic, R. Gottardo, S. H. Kleinstein, M. M. Davis, HIPC Steering Committee, Computational resources for high-dimensional immune analysis from the Human Immunology Project Consortium. Nat. Biotechnol. 32, 146-148 (2014).
2. B. Pulendran, S. Li, H. I. Nakaya, Systems vaccinology. Immunity 33, 516-529 (2010).
3. B. Pulendran, Learning immunology from the yellow fever vaccine: Innate immunity to systems vaccinology. Nat. Rev. Immunol. 9, 741-747 (2009).
4. S. Li, N. Rouphael, S. Duraisingham, S. Romero-Steiner, S. Presnell, C. Davis, D. S. Schm idt, S. E. Johnson, A. Milton, G. Rajam, S. Kasturi, G. M. Carlone, C. Quinn, D. Chaussabel, A. K. Palucka, M. J. Mulligan, R. Ahmed, D. S. Stephens, H. I. Nakaya, B. Pulendran, Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. Nat. Immunol. 15, 195-204 (2014).
5. S. von Gunten, D. F. Smith, R. D. Cummings, S. Riedel, S. Miescher, A. Schaub, R. Hamilton, B. S. Bochner, Intravenous immunoglobulin contains a broad repertoire of anti-carbohydrate antibodies that is no restricted to the IgG2 subclass. J. Allergy Clin. Immunol. 123, 1268-1276 (2009).
6. N. K. Surana, D. L. Kasper, The yin yang of bacterial polysaccharides: Lessons learned from B. Fragilis PSA. Immunol. Rev. 245, 13-26 (2012).
7. C. G. Whitney, M. M. Farley, J. Hadler, L. H. Harrison, N. M. Bennett, R. Lynfield, A. Reingold, P. R. Cieslak, T. Pilishvili, D. Jackson, R. R. Facklam, J. H. Jorgensen, A. Schuchat, Active Bacterial Core Surveillance of the Emerging Infecti o ns Program Network, Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N. Engl. J. Med. 348, 1737-1746 (2003).
8. C. Feldman, R. Anderson, Review : Current and new generation pneumococcal vaccines. J. Infect. 69, 309-325 (2014).
9. M. W. Pletz, U. Maus, N. Krug, T. Welte, H. Lode, Pneumococcal vaccines: Mechanism of action, impa ct on epidemiology and adaption of the species. Int. J. Antimicrob. Agents 32, 199-206 (2008).
10. K. K. Kamboj H. L. Kirchner R. Kimmel N. S. Greenspan J. R. Schreiber. Significant variation in serotype-specific immunogenicity of the seven-valent Streptococcus pneumoniae capsular polysaccharide-CRM197 conjugate vaccine occurs despite vigorous T cell help induced by the carrier protein. J. Infect. Dis. 187 1629-1638 (2003)
11. E. G. Leonard, D. H. Canaday, C. V. Harding, J. R. Schreiber, Antigen processing of the heptavalent pneumococcal conjugate vaccine carrier protein CRM197 differs depending on the serotype of the attached polysacchar ide. Infect. Immun. 71, 4186-4189 (2003).
12. T. Grader-Beck, F. Boin, S. von Gunten, D. Smith, A. Rosen, B. S. Bochner, Antibodies recognising sulfated carbohydrates are prevalent in systemic sclerosis and associated with pulmonary vascular disease. Ann. Rheum. Dis. 70, 2218-2224 (2011).
13. A. Madi, I. Hecht, S. Bransburg-Zabary, Y. Merbl, A. Pick, M. Zucker-Toledano, F. J. Quintana, A. I. Tauber, I. R. Cohen, E. Ben-Jacob, Organization of the autoantibody repertoire in healthy newborns and adults revealed by system level informatics of antigen microarray data. Proc. Natl. Acad. Sci. U.S.A. 106, 14484-14489 (2009).
14. A. Varki, Glycan-based interactions involving vertebrate sialic-acid-recognizing proteins. Nature 446, 1023-1029 (2007).
15. C. Jandus, H. U. Simon, S. von Gunten, Targeting Siglecs-A novel pharmacological strategy for immuno-and glycotherapy. Biochem. Pharmacol. 82, 323-332 (2011).
16. S. von Gunten, B. S. Bochner, Basic and clinical immunology of Siglecs. Ann. N. Y. Acad. Sci. 1143, 61-82 (2008).
17. S. von Gunten, S. Yousefi, M. Seitz, S. M. Jakob, T. Schaffner, R. Seger, J. Tak ala, P. M. Villiger, H. U. Simon, Siglec-9 transduces apoptotic and non-apoptotic death signals into neutrophils depending on the pro-inflammatory cytokine environment. Blood 106, 1423-1431 (2005).
18. N. Sharon, Carbohydrates as future anti-adhesion drugs for infectious diseases. Biochim. Biophys. Acta 1760, 527-537 (2006).
19. D. Cozens, R. C. Read, Anti-adhesion methods as novel therapeutics for bacterial infections. Expert Rev. Anti. Infect. Ther. 10, 1457-1468 (2012).
20. M. M. Fuster, J. D. Esko, The sweet and sour of cancer: Glycans as novel therapeutic targets. Nat. Rev. Cancer 5, 526-542 (2005).
21. J. Heimburg-Molinaro, M. Lum, G. Vijay, M. Jain, A. Almogren, K. Rittenhouse-Olson, Cancer vaccines and carbohydrate epitopes. Vaccine 29, 8802-8826 (2011).
22. C. Jandus, K. F. Boligan, O. Chijioke, H. Liu, M. Dahlhaus, T. Démoulins, C. Schneider, M. Wehrli, R. E. Hunger, G. M. Baerlocher, H. U. Simon, P. Romero, C. Mü nz, S. von Gunten, Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance. J. Clin. Invest. 124, 1810-1820 (2014).
23. Y. Onodera, J. M. Nam, M. J. Bissell, Increased sugar uptake promotes oncogenesis via EPAC/RAP1 and O-GlcNAc pathways. J. Clin. Invest. 124, 367-384 (2014).
24. M. E. Huflejt, M. Vuskovic, D. Vasiliu, H. Xu, P. Obukhova, N. Shilova, A. Tuzikov, O. Galanina, B. Arun, K. Lu, N. Bovin, Anti-carbohydrate antibodies of normal sera: Findings, surprises and challenges. Mol. Immunol. 46, 3037-3049 (2009).
25. S. R. Stowe ll, C. M. Arthur, R. McBride, O. Berger, N. Razi, J. Heimburg-Molinaro, L. C. Rodrigues, J. P. Gourdine, A. J. Noll, S. von Gunten, D. F. Smith, Y. A. Knirel, J. C. Paulson, R. D. Cummings, Microbia l glycanmicroarrays define key features of host-microbial interactions. Nat. Chem. Biol. 10, 470-476 (2014).
26. A. Pashov, B. Monzavi-Karbassi, T. Kieber-Emmons, Immune surveillance and immunotherapy: Lessons from carbohydrate mimotopes. Vaccine 27, 3405-3415 (2009).
27. I. Djoumerska, A. Tchorbanov, A. Pashov, T. Vassilev, The autoreactivity of therapeutic intravenous immunoglobulin (IVIG ) preparations depends on the fractionation methods used. Scand. J. Immunol. 61, 357-363 (2005).
28. J. P. Bouvet, D. Stahl, S. Rose, C. P. Quan, M. D. Kazatchkine, S. V. Kaveri, Induction of natural autoantibody activity following treatment of human immunoglobulin with dissociating agents. J. Autoimmun. 16, 163-172 (2001).
29. W. F. Riesen, F. Skvaril, D. G. Braun, Natural infection of man with group A streptococci. Levels; restriction in class, subclass, and type; and clonal appearance of polysaccharide-group-specific antibodies. Scand. J. Immunol. 5, 383-390 (1976).
30. W. J. Yount, M. M. Dorner, H. G. Kunkel, E. A. Kabat, Studies on human antibodies. VI. Selective variations in subgroup composition and genetic markers. J. Exp. Med. 127, 633-646 (1968).
31. M. Cohen A. Varki The sialome-Far more than the sum of its parts OMICS 14 455-464(2010).
32. A. N. Samraj, H. Lä ubli, N. Varki, A. Varki, Involvement of a non-human sialic acid in human cancer. Front. Oncol. 4, 33 (2014).
33. R. Amon, E. M. Reuven, S. Leviatan Ben-Arye, V. Padler-Karavani, Glycans in immune recognition and response. Carbohydr. Res. 389, 115-122 (2014).
34. V. Padler-Karavani, H. Yu, H. Cao, H. Chokhawala, F. Karp, N. Varki, X. Chen, A. Varki, Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: Potential implications for disease. Glycobiology 18, 818-830 (2008).
35. P. Brandtz aeg, The mucosal immune system and its integration with the mammary glands. J. Pediatr. 156, S8-S15 (2010).
36. J. B. Robbins, R. Schneerson, S. C. Szu, Perspective: Hypothesis: Serum IgG antib ody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J. Infect. Dis. 171, 1387-1398 (1995).
37. R. I. Glass, U. D. Parashar, M. K. Estes, Norovirus gastroenteritis. N. Engl. J. Med. 361, 1776-1785 (2009).
38. P. Frange, F. Touzot, M. Debré, S. Héritier, M. Leruez-Ville, G. Cros, C. Rouzioux, S. Blanche, A. Fischer, V. Avettand-Fenoël, Pr evalence and clinical impact of norovirus fecal shedding in children with inherited immune deficiencies. J. Infect. Dis. 206, 1269-1274 (2012).
39. P. I. Kitov, J.M. Sadowska, G.Mulvey, G.D. Armstrong,H. Ling, N. S. Pannu, R. J. Read, D. R. Bundle, Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands. Nature 403, 669-672 (2000).
40. E. A. Merritt, S. Sarfaty, F. van den Akker, C. L'Hoir, J. A. Martial, W. G.Hol, Crystal structure of cholera toxin B-pentamer bound to receptor GM1 pentasaccharide. Protein Sci. 3, 166-175 (1994).
41. S. J. Thorpe, B. F ox, G. Sharp, A. B. Heath, M. E. Behr-Gross, E. Terao, M. L. Virata-Theimer, M. W. Yu, International collaborative study to evaluate candidate reference reagents to standardize haemagglutination testing for anti-A and anti-B i n normal intravenous immunoglobulin products. Vox Sang. 97, 160-168 (2009).
42. F. Dhainaut, P. O. Guillaumat, H. Dib, G. Perret, A. Sauger, C. de Coupade, M. Beaudet, M. Elzaabi, L. Mouthon, In vitro and in vivo properties differ among liquid intravenous immunoglobulin preparat ions. Vox Sang. 104, 115-126 (2013).
43. C. M. Snapper, Differential regulation of protein-and polysaccharide-specific Ig isotype production in vivo in response to intact Streptococcus pneumoniae. Curr. Pr otein Pept. Sci. 7, 295-305 (2006).
44. F. Y. Avci, X. Li, M. Tsuji, D. L. Kasper, A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design. Nat. Med. 17, 1602-1609 (2011).
45. R. D. Astronomo, D. R. Burton, Carbohydrate vaccines: Developing sweet solutions to sticky situations? Nat. Rev. Drug Discov. 9, 308-324 (2010).
46. C. E. Taylor, B. A. Cobb, K. Rittenhouse-Olson, J. C. Paulson, J. R. Schreiber, Carbohydrate moieties as vaccine candidates: Targeting the sweet spot in the immune response. Vaccine 30, 4409-4413 (2012).
47. A. H. Lucas, K. Rittenhouse-Olson, M. Kronenberg, M. A. Apicella, D. Wang, J. R. Schreiber, C. E. Taylor, Carbohydrate moieties as vaccine candidates: Meeting summary. Vaccine 28, 1121-1131 (2010).
48. B. A. Cobb, Q. Wang, A. O. Tzianabos, D. L. Kasper, Polysaccharide processing and presentation by the MHCII pathway. Cell 117, 677-687 (2004).
49. W. M. Kalka-Moll, A. O. Tzianabos, P. W. Bryant, M. Niemeyer, H. L. Ploegh, D. L. Kasper, Zwitterionic polysaccharides stimulate T cells by MHC class II-dependent interactions. J. Immunol. 169, 6149-6153 (2002).
50. G. Cunto-Amesty, P. Luo, B. Monzavi-Karbassi, A. Lees, J. Alexander,M. F. del Guercio, M. H. Nahm, C. Artaud, J. Stanley, T. Kieber-Emmons, Peptide mimoto pes as prototypic templates of broadspectrum surrogates of carbohydrate antigens. Cell. Mol. Biol. 49, 245-254 (2003).
51. D. J. Barrett, E. M. Ayoub, IgG2 subclass restriction of antibody to pneumococcal polysaccharides. Clin. Exp. Immunol. 63, 127-134 (1986).
52. I. R. Cohen, The cognitive paradigm and the immunological homunculus. Immunol. Today 13, 490-494 (1992).
53. A F. Carlin S. Uchiyama Y. C. Chang A. L. Lewis V. Nizet A. Varki Molecular mimicry of host sialylated glycans allows a bacterial pathogen to engage neutrophil Siglec-9 and dampen the innate immune response Blood 113 3333-3336(2009).
54. Y. C. Chang, J. Olson, F. C. Beasley, C. Tung, J. Zhang, P. R. Crocker, A. Varki, V. Nizet, Group B Streptococcus engages an inhibitory Siglec through sialic acid mimicry to blunt innate immune and inflammatory responses in vivo. PLOS Pathog. 10, e1003846 (2014).
55. L. D. Felton, G. H. Bailey, Biologic significance of the soluble specific substances of pneumococci. J. Infect. Dis. 38, 131-144 (1926).
56. E. A. Clutterbuck, R. Lazarus, L. M. Yu, J. Bowman, E. A. Bateman, L. Diggle, B. Angus, T. E. Peto, P. C. Beverley, D. Mant, A. J. Pollard, Pneumococcal conjugate and plain polysaccharide vac cines have divergent effects on antigen-specific B cells. J. Infect. Dis. 205, 1408-1416 (2012).
57. D. Zopf, S. Roth, Oligosaccharide anti-infective agents. Lancet 347, 1017-1021 (1996).
58. T. L. Vassilev, M. D. Kazatchkine, J. P. Duong Van Huyen, M. Mekrache, E. Bonnin, J. C. Mani, C. Lecroubier, D. Korinth, D. Baruch, F. Schriever, S. Kaveri, Inhibition of cell adhesion by antibodies to Arg-Gly-Asp (RGD) in normal immunoglobulin for therapeutic use (intravenous immunoglobulin, IVIg). Blood 93, 3624-3631 (1999).
59. S. V. Kaveri, Intravenous immunoglobulin: Exploiting the potential of natural antibodies. Autoimmun. Rev. 11, 792-794 (2012).
60. A. Schaub, S. von Gunten, M. Vogel, S. Wymann, M. Rüegsegger, B. M. Stadler, M. Spycher, H. U. Simon, S. Miescher, Dimeric IVIG contains natural anti-Siglec-9 autoantibodies and their anti-idiotypes. Allergy 66, 1030-1037 (2011).
61. M. D. Kazatchkine, S. V. Kaveri, Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N. Engl. J. Med. 345, 747-755 (2001).
62. S. von Gunten, M. Vogel, A. Schaub, B. M. Stadler, S. Miescher, P. R. Crocker, H. U. Simon, Intravenous immunoglobulin preparations contain anti-Siglec-8 autoantibodies. J. Allergy Clin. Immunol. 119, 1005-1011 (2007).
63. O. Blixt, S. Head, T. Mondala, C. Scanlan, M. E. Huflejt, R. Alvarez, M. C. Bryan, F. Fazio, D. Calarese, J. Stevens, N. Razi, D. J. Stevens, J. J. Skehe l, I. van Die, D. R. Burton, I. A. Wilson, R. Cummings, N. Bovin, C. H. Wong, J. C. Paulson, Printed covalent glycan array for ligand profiling of diverse glycan binding proteins. Proc. Natl. Acad. Sci. U.S.A. 101, 17033-17038 (2004).
64. G. Shankar, V. Devanarayan, L. Amaravadi, Y. C. Barrett, R. Bowsher, D. Finco-Kent, M. Fiscella, B. Gorovits, S. Kirschner, M. Moxness, T. Parish, V. Quarmby , H. Smith, W. Smith, L. A. Zuckerman, E. Koren, Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J. Pharm. Biomed. Anal. 48, 1267-1281 (2008).